Current strategies in immunotherapy for acute myeloid leukemia

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist14,240–252 (2009).Crossref, Medline, CAS, Google Scholar
• 2  Barrett AJ, Le Blanc K. Immunotherapy prospects for acute myeloid leukaemia. Clin. Exp. Immunol.161,223–232 (2010).Medline, CAS, Google Scholar
• 3  Kadowaki N, Kitawaki T. Recent advance in antigen-specific immunotherapy for acute myeloid leukemia. Clin. Dev. Immunol.2011,104926 (2011).Crossref, Medline, Google Scholar
• 4  Smits EL, Lee C, Hardwick N et al. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunol. Immunother.60,757–769 (2011).Crossref, Medline, Google Scholar
• 5  Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature480,480–489 (2011).Crossref, Medline, CAS, Google Scholar
• 6  Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim. Biophys. Acta1776,108–123 (2007).Medline, CAS, Google Scholar
• 7  Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol.26,5275–5283 (2008).Crossref, Medline, CAS, Google Scholar
• 8  Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia26,2019–2026 (2012).Crossref, Medline, CAS, Google Scholar
• 9  Sanchez-Correa B, Morgado S, Gayoso I et al. Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol. Immunother.60,1195–1205 (2011).Crossref, Medline, CAS, Google Scholar
• 10  Baessler T, Krusch M, Schmiedel BJ et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res.69,1037–1045 (2009).Crossref, Medline, CAS, Google Scholar
• 11  Baessler T, Charton JE, Schmiedel BJ et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood115,3058–3069 (2010).Crossref, Medline, CAS, Google Scholar
• 12  Coles SJ, Wang EC, Man S et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia25,792–799 (2011).Crossref, Medline, CAS, Google Scholar
• 13  Chamuleau ME, Ossenkoppele GJ, van Rhenen A et al. High TRAILR3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAILR2. Leuk. Res.35,741–749 (2011).Crossref, Medline, CAS, Google Scholar
• 14  Ragusa M, Avola G, Angelica R et al. Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy. BMC Cancer10,377 (2010).Crossref, Medline, Google Scholar
• 15  Le Dieu R, Taussig DC, Ramsay AG et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood114,3909–3916 (2009).Crossref, Medline, CAS, Google Scholar
• 16  Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood118,5084–5095 (2011).Crossref, Medline, CAS, Google Scholar
• 17  van Luijn MM, van den Ancker W, Chamuleau ME, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA. Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. Immunotherapy2,85–97 (2010).Link, CAS, Google Scholar
• 18  van Luijn MM, van den Ancker W, Chamuleau ME et al. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4⁺ T cells. Cancer Res.71,2507–2517 (2011).Crossref, Medline, CAS, Google Scholar
• 19  Norde WJ, Hobo W, van der Voort R, Dolstra H. Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood120,728–736 (2012).Crossref, Medline, CAS, Google Scholar
• 20  Scholl N, Loibl J, Kremser A et al. The role of soluble and cell-surface expressed 4-1BB ligand in patients with malignant hemopoietic disorders. Leuk. Lymphoma50,427–436 (2009).Crossref, Medline, CAS, Google Scholar
• 21  Curti A, Aluigi M, Pandolfi S et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia21,353–355 (2007).Crossref, Medline, CAS, Google Scholar
• 22  Aurelius J, Thorén FB, Akhiani AA et al. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis. Blood119,5832–5837 (2012).Crossref, Medline, CAS, Google Scholar
• 23  Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol.8,59–73 (2008).Crossref, Medline, CAS, Google Scholar
• 24  Obeid M, Tesniere A, Ghiringhelli F et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med.13,54–61 (2007).Crossref, Medline, CAS, Google Scholar
• 25  Blum W, Klisovic RB, Becker H et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J. Clin. Oncol.28,4919–4925 (2010).Crossref, Medline, CAS, Google Scholar
• 26  Almstedt M, Blagitko-Dorfs N, Duque-Afonso J et al. The DNA demethylating agent 5aza-2´deoxycytidine induces expression of NYESO1 and other cancer/testis antigens in myeloid leukemia cells. Leuk. Res.34,899–905 (2010).Crossref, Medline, CAS, Google Scholar
• 27  Goodyear OC, Dennis M, Jilani NY et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood119,3361–3369 (2012).Crossref, Medline, CAS, Google Scholar
• 28  Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res.15,5323–5337 (2009).Crossref, Medline, Google Scholar
• 29  Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia26,2186–2196 (2012).Crossref, Medline, CAS, Google Scholar
• 30  Graf C, Heidel F, Tenzer S et al. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8⁺ T cells. Blood109,2985–2988 (2007).Crossref, Medline, CAS, Google Scholar
• 31  Greiner J, Ono Y, Hofmann S et al. Mutated regions of nucleophosmin 1 elicit both CD4⁺ and CD8⁺ T-cell responses in patients with acute myeloid leukemia. Blood120,1282–1289 (2012).Crossref, Medline, CAS, Google Scholar
• 32  Van Driessche A, Berneman ZN, Van Tendeloo VF. Active specific immunotherapy targeting the Wilms’ tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist17,250–259 (2012).Crossref, Medline, CAS, Google Scholar
• 33  Majeti R, Becker MW, Tian Q et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl Acad. Sci. USA106,3396–3401 (2009).Crossref, Medline, CAS, Google Scholar
• 34  Van Tendeloo VF, Van de Velde A, Van Driessche A et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA107,13824–13829 (2010).▪▪ A clinical Phase I/II study of vaccination with WT1-mRNA-electroporated dendritic cells showed impressive clinical results for selected high-risk acute myeloid leukemia (AML) patients. Clinical responses were correlated with frequencies of activated NK cells and antigen-specific T cells.Crossref, Medline, CAS, Google Scholar
• 35  Gal H, Amariglio N, Trakhtenbrot L et al. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia20,2147–2154 (2006).Crossref, Medline, CAS, Google Scholar
• 36  Ochsenreither S, Majeti R, Schmitt T et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood119,5492–5501 (2012).Crossref, Medline, CAS, Google Scholar
• 37  Gerber JM, Qin L, Kowalski J et al. Characterization of chronic myeloid leukemia stem cells. Am. J. Hematol.86,31–37 (2011).Crossref, Medline, Google Scholar
• 38  Rezvani K, Yong AS, Tawab A et al.Ex vivo characterization of polyclonal memory CD8⁺ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood113,2245–2255 (2009).Crossref, Medline, CAS, Google Scholar
• 39  Amir AL, van der Steen DM, van Loenen MM et al. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin. Cancer Res.17,5615–5625 (2011).Crossref, Medline, CAS, Google Scholar
• 40  Gialeli CH, Kletsas D, Mavroudis D, Kalofonos HP, Tzanakakis GN, Karamanos NK. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Curr. Med. Chem.16,3797–3804 (2009).Crossref, Medline, CAS, Google Scholar
• 41  Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363,711–723 (2010).Crossref, Medline, CAS, Google Scholar
• 42  Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N. Engl. J. Med.366,2008–2016 (2012).Crossref, Medline, CAS, Google Scholar
• 43  Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood119,6198–6208 (2012).Crossref, Medline, CAS, Google Scholar
• 44  Feldman EJ, Brandwein J, Stone R et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol.23,4110–4116 (2005).Crossref, Medline, CAS, Google Scholar
• 45  Rosenblat TL, McDevitt MR, Mulford DA et al. Sequential cytarabine and α-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin. Cancer Res.16,5303–5311 (2010).Crossref, Medline, CAS, Google Scholar
• 46  Lapusan S, Vidriales MB, Thomas X et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest. New Drugs30,1121–1131 (2012).Crossref, Medline, CAS, Google Scholar
• 47  Bross PF, Beitz J, Chen G et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res.7,1490–1496 (2001).Medline, CAS, Google Scholar
• 48  Petersdorf S, Kopecky K, Stuart RK et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood114, Abstract 790 (2009).Crossref, Google Scholar
• 49  Lo-Coco F, Cimino G, Breccia M et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood104,1995–1999 (2004).Crossref, Medline, CAS, Google Scholar
• 50  Ravandi F, Estey E, Jones D et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J. Clin. Oncol.27,504–510 (2009).Crossref, Medline, CAS, Google Scholar
• 51  Burnett AK, Hills RK, Milligan D et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J. Clin. Oncol.29,369–377 (2011).Crossref, Medline, CAS, Google Scholar
• 52  Castaigne S, Pautas C, Terré C et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, Phase 3 study. Lancet379,1508–1516 (2012).▪▪ A recent Phase III clinical trial testing the addition of low-fractionated-dose gemtuzumab ozogamicin to standard therapy for patients with newly diagnosed AML showed safe delivery of high cumulative antibody doses and substantial improvements in clinical outcome.Crossref, Medline, CAS, Google Scholar
• 53  Burnett AK, Russell NH, Hills RK et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J. Clin. Oncol.30(32),3924–3931 (2012).Crossref, Medline, CAS, Google Scholar
• 54  Amadori S, Suciu S, Stasi R et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML15B, a Phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche Dell’Adulto Leukemia groups. Leukemia19,1768–1773 (2005).Crossref, Medline, CAS, Google Scholar
• 55  Taksin AL, Legrand O, Raffoux E et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia21,66–71 (2007).Crossref, Medline, CAS, Google Scholar
• 56  Farhat H, Reman O, Raffoux E et al. Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50–70-year old: a Phase 1/2 study of the acute leukemia French association. Am. J. Hematol.87,62–65 (2012).Crossref, Medline, CAS, Google Scholar
• 57  Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood116,5089–5102 (2010).Crossref, Medline, CAS, Google Scholar
• 58  Piloto O, Levis M, Huso D et al. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res.65,1514–1522 (2005).Crossref, Medline, CAS, Google Scholar
• 59  Hofmann M, Große-Hovest L, Nübling T et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia26,1228–1237 (2012).Crossref, Medline, CAS, Google Scholar
• 60  Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene30,1009–1019 (2011).Crossref, Medline, CAS, Google Scholar
• 61  Zhao X, Singh S, Pardoux C et al. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica95,71–78 (2010).Crossref, Medline, CAS, Google Scholar
• 62  Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med.12,1167–1174 (2006).Crossref, Medline, Google Scholar
• 63  Majeti R, Chao MP, Alizadeh AA et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell138,286–299 (2009).Crossref, Medline, CAS, Google Scholar
• 64  Jin L, Lee EM, Ramshaw HS et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell5,31–42 (2009).Crossref, Medline, CAS, Google Scholar
• 65  Stein C, Kellner C, Kügler M et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br. J. Haematol.148,879–889 (2010).Crossref, Medline, CAS, Google Scholar
• 66  Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res.17,6958–6962 (2011).Crossref, Medline, CAS, Google Scholar
• 67  Zhong RK, Loken M, Lane TA, Ball ED. CTLA4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Cytotherapy8,3–12 (2006).Crossref, Medline, CAS, Google Scholar
• 68  Bashey A, Medina B, Corringham S et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood113,1581–1588 (2009).Crossref, Medline, CAS, Google Scholar
• 69  Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood114,1545–1552 (2009).Crossref, Medline, CAS, Google Scholar
• 70  Zhou Q, Munger ME, Highfill SL et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood116,2484–2493 (2010).Crossref, Medline, CAS, Google Scholar
• 71  Zhou Q, Munger ME, Veenstra RG et al. Coexpression of Tim-3 and PD-1 identifies a CD8⁺ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood117,4501–4510 (2011).Crossref, Medline, CAS, Google Scholar
• 72  Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT011, a humanized antibody interacting with PD1, in patients with advanced hematologic malignancies. Clin. Cancer Res.14,3044–3051 (2008).Crossref, Medline, CAS, Google Scholar
• 73  Lanier LL. NK cell recognition. Annu. Rev. Immunol.23,225–274 (2005).Crossref, Medline, CAS, Google Scholar
• 74  Venstrom JM, Pittari G, Gooley TA et al. HLAC-dependent prevention of leukemia relapse by donor activating KIR2DS1. N. Engl. J. Med.367,805–816 (2012).▪ The HLA genotypes of 1277 patients after allogeneic hematopoietic stem cell transplantation and corresponding donor HLA and killer-cell immunoglobulin-like receptor genotypes were assessed. Specific donor killer-cell immunoglobulin-like receptor genes were shown to provide protection against relapse in a HLA-C-dependent manner.Crossref, Medline, CAS, Google Scholar
• 75  Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood105,3051–3057 (2005).Crossref, Medline, CAS, Google Scholar
• 76  Guo M, Hu KX, Yu CL et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood117,936–941 (2011).Crossref, Medline, CAS, Google Scholar
• 77  Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol.12,269–281 (2012).Crossref, Medline, CAS, Google Scholar
• 78  Kolb HJ, Mittermüller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood76,2462–2465 (1990).Crossref, Medline, CAS, Google Scholar
• 79  Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol.15,433–444 (1997).Crossref, Medline, Google Scholar
• 80  Schmid C, Labopin M, Nagler A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J. Clin. Oncol.25,4938–4945 (2007).Crossref, Medline, CAS, Google Scholar
• 81  Soiffer RJ. Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract. Res. Clin. Haematol.21,455–466 (2008).Crossref, Medline, CAS, Google Scholar
• 82  Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol.163,507–513 (1999).Medline, CAS, Google Scholar
• 83  Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314,126–129 (2006).Crossref, Medline, CAS, Google Scholar
• 84  Xue SA, Gao L, Hart D et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood106,3062–3067 (2005).Crossref, Medline, CAS, Google Scholar
• 85  Perro M, Tsang J, Xue SA et al. Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer. Gene Ther.17,721–732 (2010).▪ Development of a lentiviral gene transfer strategy to generate T-cell receptor-transduced human T cells against WT1 is described.Crossref, Medline, CAS, Google Scholar
• 86  Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8⁺ T cells derived from central memory cells establishes persistent T-cell memory in primates. J. Clin. Invest.118,294–305 (2008).Crossref, Medline, CAS, Google Scholar
• 87  Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA90,720–724 (1993).Crossref, Medline, CAS, Google Scholar
• 88  Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood116,1035–1044 (2010).Crossref, Medline, CAS, Google Scholar
• 89  Uttenthal BJ, Chua I, Morris EC, Stauss HJ. Challenges in T-cell receptor gene therapy. J. Gene Med.14,386–399 (2012).Crossref, Medline, CAS, Google Scholar
• 90  Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med.365,725–733 (2011).Crossref, Medline, CAS, Google Scholar
• 91  Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood119,2709–2720 (2012).▪ Proof-of-concept trial using anti-CD19 chimeric antigen receptor-transduced T cells and a course of IL-2 after lymphodepleting chemotherapy in patients with advanced B-cell lymphoma.Crossref, Medline, CAS, Google Scholar
• 92  Baer MR, George SL, Caligiuri MA et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J. Clin. Oncol.26,4934–4939 (2008).Crossref, Medline, CAS, Google Scholar
• 93  Brune M, Castaigne S, Catalano J et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized Phase 3 trial. Blood108,88–96 (2006).▪ Phase III study demonstrating that treatment with histamine dihydrochloride and IL-2 significantly improved leukemia-free survival compared with no treatment in the overall population and in patients in first complete remission.Crossref, Medline, CAS, Google Scholar
• 94  Koreth J, Matsuoka K, Kim HT et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med.365,2055–2066 (2011).Crossref, Medline, CAS, Google Scholar
• 95  Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol. Rev.241,63–76 (2011).Crossref, Medline, CAS, Google Scholar
• 96  Waldmann TA, Lugli E, Roederer M et al. Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood117,4787–4795 (2011).Crossref, Medline, CAS, Google Scholar
• 97  Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood111,236–242 (2008).Crossref, Medline, CAS, Google Scholar
• 98  Rezvani K, Yong AS, Mielke S et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8⁺ T cells in myeloid malignancies. Haematologica96,432–440 (2011).Crossref, Medline, CAS, Google Scholar
• 99  Keilholz U, Letsch A, Busse A et al. A clinical and immunologic Phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood113,6541–6548 (2009).Crossref, Medline, CAS, Google Scholar
• 100  Ochsenreither S, Fusi A, Busse A et al. “Wilms Tumor Protein 1” (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J. Immunother.34,85–91 (2011).Crossref, Medline, CAS, Google Scholar
• 101  Ochsenreither S, Fusi A, Geikowski A et al. Wilms’ tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer Immunol. Immunother.61,313–322 (2012).Crossref, Medline, CAS, Google Scholar
• 102  Schmitt M, Schmitt A, Rojewski MT et al. RHAMMR3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood111,1357–1365 (2008).Crossref, Medline, CAS, Google Scholar
• 103  Greiner J, Schmitt A, Giannopoulos K et al. High-dose RHAMMR3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica95,1191–1197 (2010).Crossref, Medline, CAS, Google Scholar
• 104  Kuball J, de Boer K, Wagner E et al. Pitfalls of vaccinations with WT1-, proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol. Immunother.60,161–171 (2011).Crossref, Medline, CAS, Google Scholar
• 105  Maslak PG, Dao T, Krug LM et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood116,171–179 (2010).▪ A pilot study of vaccination with a polyvalent WT1 vaccine including long as well as heteroclitic peptides demonstrated antigen-specific T-cell responses in seven out of eight evaluable AML patients.Crossref, Medline, CAS, Google Scholar
• 106  Borrello IM, Levitsky HI, Stock W et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood114,1736–1745 (2009).Crossref, Medline, CAS, Google Scholar
• 107  Ingram W, Chan L, Guven H et al. Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a Phase I clinical study. Br. J. Haematol.145,749–760 (2009).Crossref, Medline, Google Scholar
• 108  Hardwick N, Chan L, Ingram W, Mufti G, Farzaneh F. Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80. Cancer Immunol. Immunother.59,379–388 (2010).Crossref, Medline, CAS, Google Scholar
• 109  Kremser A, Dressig J, Grabrucker C et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J. Immunother.33,185–199 (2010).Crossref, Medline, Google Scholar
• 110  Ge W, Ma X, Li X et al. B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells. Leuk. Res.33,948–957 (2009).Crossref, Medline, CAS, Google Scholar
• 111  Curti A, Trabanelli S, Onofri C et al. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells. Haematologica95,2022–2030 (2010).Crossref, Medline, CAS, Google Scholar
• 112  Li L, Giannopoulos K, Reinhardt P et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. Int. J. Oncol.28,855–861 (2006).Medline, CAS, Google Scholar
• 113  Roddie H, Klammer M, Thomas C et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br. J. Haematol.133,152–157 (2006).Crossref, Medline, CAS, Google Scholar
• 114  Draube A, Beyer M, Wolf J. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells. Eur. J. Haematol.81,281–288 (2008).Crossref, Medline, Google Scholar
• 115  Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum. Vaccin.7,579–584 (2011).Crossref, Medline, CAS, Google Scholar
• 116  Serrano-López J, Sanchez-Garcia J, Serrano J et al. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia. Transfusion51,1546–1555 (2011).Crossref, Medline, CAS, Google Scholar
• 117  Mohib K, Wang L. Differentiation and characterization of dendritic cells from human embryonic stem cells. Curr. Protoc. Immunol. Chapter 22, Unit22F.11 (2012).Medline, Google Scholar
• 118  van de Ven R, Reurs AW, Wijnands PG et al. Exposure of CD34⁺ precursors to cytostatic anthraquinone-derivatives induces rapid dendritic cell differentiation: implications for cancer immunotherapy. Cancer Immunol. Immunother.61,181–191 (2012).Crossref, Medline, Google Scholar
• 119  Spranger S, Frankenberger B, Schendel DJ. NOD/SCID IL-2Rγ(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J. Transl Med.10,30 (2012).Crossref, Medline, CAS, Google Scholar
• 120  Lee JJ, Kook H, Park MS et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J. Clin. Apher.19,66–70 (2004).Crossref, Medline, Google Scholar
• 121  Van Driessche A, Van de Velde AL, Nijs G et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a Phase I dose-escalation clinical trial. Cytotherapy11,653–668 (2009).Crossref, Medline, CAS, Google Scholar
• 122  Berneman ZN, Van de Velde A, Anguille S et al. WT1-targeted dendritic cell vaccination as a postremission treatment to prevent or delay relapse in acute myeloid leukemia. J. Clin. Oncol.30, Abstract 2506 (2012).Crossref, Google Scholar
• 123  Kitawaki T, Kadowaki N, Fukunaga K et al. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Exp. Hematol.39,424–433.e2 (2011).Crossref, Medline, CAS, Google Scholar
• 124  Kitawaki T, Kadowaki N, Fukunaga K et al. A Phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Br. J. Haematol.153,796–799 (2011).Crossref, Medline, CAS, Google Scholar
• 125  Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol.27,3135–3142 (1997).Crossref, Medline, CAS, Google Scholar
• 126  van den Ancker W, van Luijn MM, Ruben JM et al. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation. Cancer Immunol. Immunother.60,37–47 (2011).Crossref, Medline, Google Scholar
• 127  Zobywalski A, Javorovic M, Frankenberger B et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J. Transl Med.5,18 (2007).Crossref, Medline, Google Scholar
• 128  Spranger S, Javorovic M, Bürdek M et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J. Immunol.185,738–747 (2010).Crossref, Medline, CAS, Google Scholar
• 129  Lichtenegger FS, Mueller K, Otte B et al. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells. PLoS ONE7,e44266 (2012).Crossref, Medline, CAS, Google Scholar
• 130  Beck B, Dörfel D, Lichtenegger FS et al. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl Med.9,151 (2011).Crossref, Medline, CAS, Google Scholar
• 201  Southwest Oncology Group: Leukemia. www.swogstat.org/ROS/ROSBooks/Spring%202010/Leukemia.pdfGoogle Scholar